Revolution Medicines, Inc.
Quick facts
| Founded | 2014 |
|---|
Marketed products
Phase 3 pipeline
- daraxonrasib · Other
- mFOLFIRINOX regimen · Oncology
mFOLFIRINOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. - RMC-6236 · Oncology
RMC-6236 is a selective inhibitor of KRAS G12C mutations that blocks oncogenic signaling in cancer cells.
Phase 2 pipeline
Phase 1 pipeline
- Drug: Osimertinib
- Elironrasib · Other
- RMC-5127
- RMC-6291
- RMC-9805
- Zoldonrasib · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Revolution Medicines, Inc.
What are Revolution Medicines, Inc.'s marketed drugs?
Top marketed products include mFOLFOX6 regimen.
What is Revolution Medicines, Inc.'s pipeline?
Revolution Medicines, Inc. has 3 drugs in Phase 3, 1 in Phase 2, 6 in Phase 1. Late-stage candidates include daraxonrasib, mFOLFIRINOX regimen, RMC-6236.
When was Revolution Medicines, Inc. founded?
Revolution Medicines, Inc. was founded in 2014.
Related
- mFOLFOX6 regimen
- Sector hub: All tracked pharma companies